A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT ID: NCT05287126
Last Updated: 2025-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
36 participants
INTERVENTIONAL
2022-12-16
2031-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
NCT03996369
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03945188
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT02536404
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
NCT04607837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etrasimod
Etrasimod
Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etrasimod
Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants are permitted to be receiving a therapeutic dose of select UC therapies
Exclusion Criteria
* Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
* Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arena is a wholly owned subsidiary of Pfizer
INDUSTRY
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Children's (IP Address)
Little Rock, Arkansas, United States
Arkansas Children's
Little Rock, Arkansas, United States
Valley View Wellness Medical Center
Garden Grove, California, United States
Loma Linda Children's Hospital
Loma Linda, California, United States
Loma Linda University Clinical Trial Center
Loma Linda, California, United States
Loma Linda University Eye Institute
Loma Linda, California, United States
Loma Linda University Medical Center
Loma Linda, California, United States
Loma Linda University Pediatric Clinics
Loma Linda, California, United States
Loma Linda University Children's Hospital Pediatric Specialty Clinics
San Bernardino, California, United States
University of California San Francisco,
San Francisco, California, United States
University of California San Francisco
San Francisco, California, United States
University of California,San Francisco Pediatric ClinicalResearch Center (PCRC)
San Francisco, California, United States
Arnold Palmer Hospital - Center for Digestive Health and Nutrition
Orlando, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
William Beaumont Hospital
Royal Oak, Michigan, United States
University of Rochester Medical Center
Rochester, New York, United States
University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital
Cleveland, Ohio, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Advance Clinical Trial PLLC
Abilene, Texas, United States
Landeskrankenhaus Salzburg
Salzburg, , Austria
University Hospitals Leuven
Leuven, , Belgium
Tsujinaka Hospital - Kashiwanoha
Kashiwa, Chiba, Japan
Ishii Eye Clinic
Nagareyama-shi, Chiba, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Hyogo Medical University Hospital
Nishinomiya, Hyōgo, Japan
Kinki University - Nara Hospital
Ikoma, Nara, Japan
Saitama Prefectural Children's Medical Center
Saitama-shi, Saitama, Japan
Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Japanese Red Cross Kyoto Daini Hospital
Kyoto, , Japan
Saga University Hospital
Saga, , Japan
Toyama Prefectural Central Hospital
Toyama, , Japan
Instytut "Pomnik - Centrum Zdrowia Dziecka" (IPCZD) (The Children's Memorial Health Institute)
Warsaw, Masovian Voivodeship, Poland
Uniwersytecki Szpital Dziecięcy w Krakowie
Krakow, , Poland
Twoja Przychodnia - Szczecińskie Centrum Medyczne
Szczecin, , Poland
Centrum Zdrowia MDM
Warsaw, , Poland
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, , Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroclaw, , Poland
Instytut Centrum Zdrowia Matki Polki
Lodz, Łódź Voivodeship, Poland
Narodny ustav detskych chorob
Bratislava, Bratislava Region, Slovakia
Cliniq s.r.o.
Bratislava, , Slovakia
Hospital Clinico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruna, Spain
Consorci Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Reina Sofia
Córdoba, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C5041010
Identifier Type: OTHER
Identifier Source: secondary_id
2022-500345-25-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
APD334-207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.